ABSTRACT
Metabolic syndrome (MetS) is very prevalent in the United States and around the world. MetS is a significant risk factor for both diabetes (T2DM) and cardiovascular disease (CVD). It is estimated that between 34%– and 39% of individuals have MetS. Insulin resistance and hyperinsulinemia are abnormalities that underpin MetS. MetS is a useful diagnosis to make since it will allow the clinician to initiate various therapeutic modalities including aggressive lifestyle therapies to help lower the risk of CVD and T2DM.
